Simulations Plus has announced a strategic partnership program with three pharmaceutical companies to advance AI-enabled modeling in drug development.
The purpose of this collaboration is to apply AI within scientifically validated modeling workflows to define next-generation approaches that are scalable across the drug development life cycle.
Discover effective B2B marketing
We combine business intelligence and editorial excellence to reach passionate professionals across 36 major media platforms.
learn more
The program uses the Simulations Plus software platform, including ADMET Predictor, GastroPlus, Thales, and MonolixSuite.
By working closely with these pharmaceutical companies, Simulations Plus aims to integrate AI into real-world environments to inform workflow standardization, product direction, and future commercial models.
Under these programs, participating companies will integrate Simulations Plus’ AI agents directly into their model-informed drug development (MIDD) workflows.
This integration supports natural language interaction, automates data processing, coordinates simulations across multiple modeling engines, and produces interpretable results from complex pipelines.
Additionally, this effort is designed to establish broader enterprise adoption. Simulations Plus and its partners work with information technology teams to define the deployment, governance, and integration of AI-enabled capabilities within existing systems.
This approach includes setting common standards for transparency and reproducibility as AI becomes more deeply integrated into the drug development process.
said Jonathan Chauvin, Co-Chief Product Technology Officer, Simulations Plus. “Our approach to AI is based on how AI works within a complete system, rather than as a standalone feature.
“These collaborations allow us to work with our partners and leverage real-time scientific feedback and enterprise data to continually improve how we orchestrate workflows across our tools, ensuring AI-driven efficiencies are linked to reproducible and traceable results.”
said Shawn O’Connor, CEO of Simulations Plus. “Our customers choose to work with us because of the strength of our validated science engine and the depth of our teams that apply it within real-world workflows every day, enabling them to transform AI into practical, deployable solutions.”
